Oteseconazole

Oteseconazole
Clinical data
Trade names	Vivjoa
Other names	VT-1161
License data	US DailyMed: Oteseconazole;
Routes of; administration	By mouth
Drug class	Antifungal
ATC code	J02AC06 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2R)-2-(2,4-Difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol;
CAS Number	1340593-59-0;
PubChem CID	77050711;
DrugBank	DB13055;
ChemSpider	52083215;
UNII	VHH774W97N;
KEGG	D11785;
ChEBI	CHEBI:188153;
ChEMBL	ChEMBL3311228;
ECHA InfoCard	100.277.989
Chemical and physical data
Formula	C23H16F7N5O2
Molar mass	527.403 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F;
	InChI InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1; Key:IDUYJRXRDSPPRC-NRFANRHFSA-N;

Oteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC) in patients.^[2]^[3]

Marketed under the brand name Vivjoa, this medication was developed by Mycovia Pharmaceuticals and received approval for medicinal use from United States Food and Drug Administration (US FDA) in April 2022.^[1]^[4]^[5]

^ ^a ^b "Vivjoa- oteseconazole capsule". DailyMed. U.S. National Library of Medicine. 12 July 2022. Retrieved 21 January 2023.
^ Sobel JD, Nyirjesy P (December 2021). "Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis". Future Microbiology. 16 (18): 1453–1461. doi:10.2217/fmb-2021-0173. PMID 34783586. S2CID 244131114.
^ De SK (2023). "Oteseconazole: First Approved Orally Bioavailable and Selective CYP51 Inhibitor for the Treatment of Patients with Recurrent Vulvovaginal Candidiasis". Current Medicinal Chemistry. 30 (37): 4170–4175. doi:10.2174/0929867330666230220130024. PMID 36803759. S2CID 257066627.
^ "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Retrieved 26 June 2023.
^ "FDA Approves Mycovia Pharmaceuticals' VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)". www.businesswire.com. 28 April 2022. Retrieved 26 June 2023.

[Vivjoa_FDA_label-1] "Vivjoa- oteseconazole capsule". DailyMed. U.S. National Library of Medicine. 12 July 2022. Retrieved 21 January 2023.

[Sobel_2021-2] Sobel JD, Nyirjesy P (December 2021). "Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis". Future Microbiology. 16 (18): 1453–1461. doi:10.2217/fmb-2021-0173. PMID 34783586. S2CID 244131114.

[De_2023-3] De SK (2023). "Oteseconazole: First Approved Orally Bioavailable and Selective CYP51 Inhibitor for the Treatment of Patients with Recurrent Vulvovaginal Candidiasis". Current Medicinal Chemistry. 30 (37): 4170–4175. doi:10.2174/0929867330666230220130024. PMID 36803759. S2CID 257066627.

[4] "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Retrieved 26 June 2023.

[5] "FDA Approves Mycovia Pharmaceuticals' VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)". www.businesswire.com. 28 April 2022. Retrieved 26 June 2023.

[1]

[2]

[3]

[4]

[5]